Literature DB >> 1970487

Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms.

A Tefferi1, S N Thibodeau, L A Solberg.   

Abstract

We used the X-linked restriction fragment length polymorphism (RFLP)-methylation strategy to study the clonal basis of the myelodysplastic syndrome (MDS) in seven patients. RFLP-methylation analysis was performed on cell populations from bone marrow (BM) aspirates and peripheral blood using probes specific for the hypoxanthine phosphoribosyltransferase (HPRT) or phosphoglycerate kinase (PGK) gene regions. Density gradient centrifugation methods were used to separate granulocytes and monocytes, and T lymphocytes were positively selected by CD2 (a pan-T marker) immunoconjugated magnetic beads. Cell populations from BM aspirates in 6 of the 7 patients with MDS showed a monoclonal pattern of X-inactivation. The neutrophilic and T-lymphocytic cell fractions were analyzed in 4 of the 6 patients, and the monocytic cell fraction in one of these, and all fractions analyzed showed a similar monoclonal pattern. In 2 of the latter 4 patients, both of whom had normal karyotypes, DNA from a skin biopsy showed a polyclonal pattern. Our data suggest that MDS is a clonal disorder, even in the absence of detectable cytogenetic abnormalities, and that the abnormal clone is capable of myeloid, monocytic, and lymphoid differentiation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970487

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Myelodysplastic syndromes.

Authors:  I M Hann
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

2.  Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction.

Authors:  D G Gilliland; K L Blanchard; J Levy; S Perrin; H F Bunn
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

3.  Three new loci for determining x chromosome inactivation patterns.

Authors:  Birgitte Bertelsen; Zeynep Tümer; Kirstine Ravn
Journal:  J Mol Diagn       Date:  2011-07-02       Impact factor: 5.568

Review 4.  The pathogenesis of chronic myeloproliferative diseases.

Authors:  A Tefferi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 5.  Clonality in the myelodysplastic syndromes.

Authors:  Jacqueline Boultwood; James S Wainscoat
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

6.  Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.

Authors:  H H Gerhartz; R Marcus; A Delmer; H Zwierzina; T de Witte; A Jacobs; G Visiani; D Fiere; P Sonneveld; B Labar
Journal:  Infection       Date:  1992       Impact factor: 3.553

7.  A novel, essential control for clonality analysis with human androgen receptor gene polymerase chain reaction.

Authors:  Jeroen P van Dijk; Leonie H Heuver; Bert A van der Reijden; Reinier A Raymakers; Theo de Witte; Joop H Jansen
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

8.  Detection of p53 mutations using nonradioactive SSCP analysis: p53 is not frequently mutated in myelodysplastic syndromes (MDS).

Authors:  A Neubauer; C Brendel; D Vogel; C A Schmidt; I Heide; D Huhn
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

Review 9.  FAB classification of myelodysplastic syndromes: merits and controversies.

Authors:  G E Verhoef; S Pittaluga; C De Wolf-Peeters; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

10.  Cytogenetic findings in 179 patients with myelodysplastic syndromes.

Authors:  D Haase; C Fonatsch; M Freund; B Wörmann; H Bodenstein; H Bartels; B Stollmann-Gibbels; E Lengfelder
Journal:  Ann Hematol       Date:  1995-04       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.